Intact Investment Management Inc. Has $10.36 Million Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Intact Investment Management Inc. boosted its stake in Gilead by 101.9% in Q4 to 84,400 shares, valued at about $10.36 million.
• Gilead has near‑term growth catalysts: the FDA granted a priority review to its bictegravir+lenacapavir HIV regimen and the company completed the roughly $7.8B Arcellx acquisition, expanding its oncology/cell‑therapy pipeline.
• Gilead beat quarterly estimates (EPS $1.86 vs. $1.83) on $7.93B revenue, set FY2026 guidance of 8.45–8.85 EPS, and raised its quarterly dividend to $0.82 (annualized yield ~2.5%).

Intact Investment Management Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 101.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 84,400 shares of the biopharmaceutical company's stock after buying an additional 42,600 shares during the quarter. Intact Investment Management Inc.'s holdings in Gilead Sciences were worth $10,359,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Elite Wealth Management Inc. grew its stake in Gilead Sciences by 3.1% in the 4th quarter. Elite Wealth Management Inc. now owns 10,109 shares of the biopharmaceutical company's stock valued at $1,241,000 after buying an additional 300 shares during the last quarter. Mcdonald Partners LLC grew its stake in Gilead Sciences by 5.0% in the 4th quarter. Mcdonald Partners LLC now owns 28,296 shares of the biopharmaceutical company's stock valued at $3,473,000 after buying an additional 1,351 shares during the last quarter. CENTRAL TRUST Co grew its stake in Gilead Sciences by 1.3% in the 4th quarter. CENTRAL TRUST Co now owns 19,763 shares of the biopharmaceutical company's stock valued at $2,426,000 after buying an additional 249 shares during the last quarter. Core Alternative Capital grew its stake in Gilead Sciences by 417.6% in the 4th quarter. Core Alternative Capital now owns 1,584 shares of the biopharmaceutical company's stock valued at $194,000 after buying an additional 1,278 shares during the last quarter. Finally, Greenfield Savings Bank grew its stake in Gilead Sciences by 7.7% in the 4th quarter. Greenfield Savings Bank now owns 9,542 shares of the biopharmaceutical company's stock valued at $1,171,000 after buying an additional 686 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $131.65 on Monday. The company has a 50-day moving average of $140.49 and a 200-day moving average of $132.55. The company has a market capitalization of $163.41 billion, a price-to-earnings ratio of 19.45, a PEG ratio of 1.74 and a beta of 0.31. Gilead Sciences, Inc. has a 52 week low of $95.29 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date was Friday, March 13th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio is 48.45%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the company a "buy" rating in a report on Wednesday, February 11th. Jefferies Financial Group assumed coverage on shares of Gilead Sciences in a report on Tuesday, March 10th. They issued a "buy" rating and a $180.00 price target for the company. TD Cowen increased their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a report on Wednesday, February 11th. Scotiabank increased their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 11th. Finally, Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, April 10th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $157.35.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares in the company, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the insider owned 128,779 shares of the company's stock, valued at $18,152,687.84. The trade was a 2.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 178,640 shares of company stock worth $26,584,250. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA gives priority review to Gilead’s once‑daily bictegravir + lenacapavir HIV regimen, shortening the path to U.S. commercialization if approved — a clear revenue and de‑risking catalyst. Read More.
• Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline and boosting longer‑term growth optionality beyond antivirals. Read More.
• Positive Sentiment: Analyst bullishness: Morgan Stanley and other shops have raised price targets/ratings recently, signaling analyst support that can attract buyers. Read More.
• Neutral Sentiment: Gilead scheduled presentations at several investor conferences (BofA, RBC, Bernstein, Goldman Sachs) — increases visibility and provides opportunities to update guidance/portfolio progress but is informational rather than a direct catalyst. Read More.
• Neutral Sentiment: Pre‑earnings coverage highlights HIV franchise strength versus cell‑therapy cost/headwinds; Wall Street expects modest earnings growth into the next print — sets expectations for the upcoming report. Read More.
• Negative Sentiment: CEO Daniel O’Day sold shares under a Rule 10b5‑1 plan (recent transactions disclosed), which can create short‑term headline pressure even if planned. Read More.
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — raises governance/IP scrutiny that could produce regulatory or PR noise around future exclusivity‑dependent revenues. Read More.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.